These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26031672)

  • 1. Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.
    Stähli BE; Gebhard C; Tardif JC
    Curr Cardiol Rep; 2015 Jul; 17(7):608. PubMed ID: 26031672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should patients with type 2 diabetes focus on glycemic control to reduce their cardiovascular risk?
    Montori VM
    Pol Arch Med Wewn; 2008 Sep; 118(9):502-7. PubMed ID: 18846985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 5. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The influence of drugs used in the treatment of diabetes type 2 on the cardio-vascular risk].
    Kern A; Zaleska M; Możeńska O; Bil J
    Wiad Lek; 2017; 70(4):827-833. PubMed ID: 29064812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease and the use of insulin.
    Kramer CK; Zinman B
    Diabetes Technol Ther; 2013 Oct; 15(10):789-91. PubMed ID: 23991630
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort.
    Roumie CL; Huizinga MM; Liu X; Greevy RA; Grijalva CG; Murff HJ; Hung AM; Griffin MR
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):36-44. PubMed ID: 21182152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):13S-20S. PubMed ID: 25623546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Overview of drug therapy in elderly diabetic patients].
    Kigawa Y; Suzuki T; Oba K
    Nihon Rinsho; 2013 Nov; 71(11):1982-6. PubMed ID: 24397170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
    Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.